Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Children’s Motrin lawsuit

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals is "aware of the report of a seven-year-old girl who has been diagnosed with Stevens-Johnson syndrome, allegedly associated with the use of Children's Motrin," the Johnson & Johnson subsidiary said, responding to a lawsuit filed in Los Angeles Superior Court Dec. 28. The firm said it is "investigating the situation." Seven-year-old Sabrina Brierton Johnson is suing J&J, McNeil, McKesson Corp., Save-On Drug Stores, Cardinal Health and Ralph's Grocery for selling the ibuprofen oral suspension knowing an allergic reaction to the drug could trigger the skin disease Stevens-Johnson syndrome, which in turn may cause blindness. Timing of the suit comes amidst increasing concerns about drug safety, and closely follows the addition of a black box warning mentioning risk of skin diseases, including Stevens-Johnson syndrome, to Pfizer's COX-2 inhibitor Bextra...

You may also be interested in...

Children’s Motrin Suit Seeks Compensation, New Label For Ibuprofen Product

A lawsuit that alleges Children's Motrin with ibuprofen caused a girl's blindness wants McNeil Consumer & Specialty Pharmaceuticals to clearly list all potential serious adverse reactions on the product's label and compensate the child

Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment

Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.

DuPont, P&G Aim To Accelerate Probiotic Sales By Developing ‘Next Generation’ Ingredients

DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts